G-CSF: Filgrastim, lenograstim and biosimilars

Expert Opinion on Biological Therapy

Volumn 14, Issue 7, 2014, Pages 983-993

  Welte, Karl ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Filgrastim; Granulocyte colony stimulating factor; Granulocyte colony stimulating factor biosimilars; Lenograstim

Indexed keywords

BIOSIMILAR AGENT; COLONY STIMULATING FACTOR; COLONY STIMULATING FACTOR 1; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; INTERLEUKIN 3; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEM CELL FACTOR; ANTINEOPLASTIC AGENT; FILGRASTIM; LENOGRASTIM; RECOMBINANT PROTEIN;

BIOCHEMICAL COMPOSITION; CANCER MORTALITY; CANCER REGRESSION; CELL DIFFERENTIATION; CELL PROLIFERATION; CHEMOTHERAPY; DISEASE FREE SURVIVAL; GENE DELETION; GRAFT VERSUS HOST REACTION; HEMATOPOIETIC STEM CELL; HUMAN; IN VIVO STUDY; LEUKEMIA CELL; LUNG SMALL CELL CANCER; MORTALITY; MYELOABLATIVE CONDITIONING; MYELOID LEUKEMIA; NEUTROPHIL; NONHUMAN; PERIPHERAL BLOOD STEM CELL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; STEM CELL MOBILIZATION; STEM CELL TRANSPLANTATION; SYSTEMATIC REVIEW; TRANSITIONAL CELL CARCINOMA; UPREGULATION; BONE MARROW TRANSPLANTATION; CHEMICALLY INDUCED; COST BENEFIT ANALYSIS; NEUTROPENIA; PROCEDURES;

ANTINEOPLASTIC AGENTS; BIOSIMILAR PHARMACEUTICALS; BONE MARROW TRANSPLANTATION; COST-BENEFIT ANALYSIS; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; NEUTROPENIA; RECOMBINANT PROTEINS; STEM CELL TRANSPLANTATION;

EID: 84902189296     PISSN: 14712598     EISSN: 17447682     Source Type: Journal    
DOI: 10.1517/14712598.2014.905537     Document Type: Review

References (61)

1. Metcalf D. The colony-stimulating factors and cancer. Nat Rev Cancer 2010;10:425-34
2. Welte K, Platzer E, Lu I, et al. Purification and biochemical characterization of human pluripotent hematopoietic colony-stimulating factor. Proc Natl Acad Sci USA 1985;82:1526-30
3. Souza LM, Boone TC, Gabrilove J, et al. Recombinant human granulocyte colonystimulating factor: effects on normal and leukemic myeloid cells. Science 1986;232:61-5
4. Nomura H, Imazeki I, Oheda M, et al. Purification and characterization of human granulocyte colony-stimulating factor (G-CSF). EMBO J 1986;5:871-6
5. Nagata S, Tsuchiya M, Asano S, et al. Molecular cloning and expression of cDNA for human granulocyte colony-stimulating factor. Nature 1986;319:415-18
6. Fukunaga R, Ishizaka-Ikeda E, Nagata S. Purification and characterization of thereceptor for murine granulocytecolony- stimulating factor. J Biol Chem 1990;265:14008-15
7. Tanaka H, Tanaka Y, Shinagawa K, et al. Three types of recombinant human granulocyte colony-stimulating factor have equivalent biological activities in monkeys. Cytokine 1997;9:360-9
8. Platzer E, Welte K, Gabrilove JL, et al. Biological activities of a human pluripotent hematopoietic colony stimulating factor on normal and leukemic cells. J Exp Med 1985;162:1788-801
9. Strife A, Lambek C, Wisniewski D, et al. Activities of four purified growth factors on highly enriched human hematopoietic progenitor cells. Blood 1987;69:1508-23
10. Lieschke GJ, Grail D, Hodgson G, et al. Mice lacking granulocyte colonystimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization. Blood 1994;84:1737-46
11. de Koning JP, Dong F, Smith L, et al. The membrane-distal cytoplasmic region of human granulocyte colony-stimulating factor receptor is required for STAT3 but not STAT1 homodimer formation. Blood 1996;87:1335-42
12. Skokowa J, Cario G, Uenalan M, et al. LEF-1 is crucial for neutrophil granulocytopoiesis and its expression is severely reduced in congenital neutropenia. Nat Med 2006;12:1191-7
13. Skokowa J, Lan D, Thakur BK, et al. NAMPT is essential for the G-CSF induced myeloid differentiation via NAD +-sirtuin-1-dependent pathway. Nat Med 2009;15:151-8
14. Skokowa J, Klimiankou M, Klimenkova O, et al. Interactions among HCLS1, HAX1 and LEF-1 proteins are essential for G-CSF-triggered granulopoiesis. Nat Med 2012;18:1550-9
15. Welte K, Bonilla MA, Gillio AP, et al. Recombinant human granulocyte colonystimulating factor. Effects on hematopoiesis in normal and cyclophosphamide-treated primates. J Exp Med 1987;165:941-8
16. Gillio AP, Bonilla MA, Potter GK, et al. Effects of recombinant human granulocyte colony stimulating factor on hematopoietic reconstitution after autologous bone marrow transplantation in primates. Transplant Proc 1987;19:153
17. Gabrilove JL, Jakubowski A, Scher H, et al. Effect of granulocyte colonystimulating factor on neutropenia and associated morbidity due to chemotherapy for transitional-cell carcinoma of the urothelium. N Engl J Med 1988;318:1414-22
18. Bronchud MH, Scarfe JH, Thatcher N, et al. Phase I/II study of recombinant human granulocyte colony-stimulating factor in patients receiving intensive chemotherapy for small cell lung cancer. Br J Cancer 1987;56:809-13
19. Crawford J, Ozer H, Stoller R, et al. Reduction by granulocyte colonystimulating factor of fever and neutropenia induced by chemotherapy in patients with small-cell lung cancer. N Engl J Med 1991;325:164-70
20. Welte K, Gabrilove J, Bronchud MH, et al. Filgrastim (r-metHuG-CSF): the first 10 years. Blood 1996;88:1907-29
21. Kuderer NM, Dale DC, Crawford J, Lyman GH. Impact of primary prophylaxis with granulocyte colony-stimulating factor on febrile neutropenia and mortality in adult cancer patients receiving chemotherapy: a systematic review. J Clin Oncol 2007;25:3158-67
22. Lyman GH, Lalla A, Barron RL, Dubois RW. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States. Clin Ther 2009;31:1092-104
23. Lowenberg B, Touw IT. Hematopoietic growth factors and their receptors in acute leukemia. Blood 1993;81:281-92
24. Ohno R, Naoe T, Kanamaru A, et al. A double-blind controlled study of granulocyte colony-stimulating factor started two days before induction chemotherapy in refractory acute myeloid leukemia. Blood 1994;83:2015-19
25. Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671-8
26. Giralt S, Escudier S, Kantarjian H, et al. Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. N Engl J Med 1993;329:757-61
27. Welte K, Reiter A, Mempel K, et al. A randomized phase III study of the efficacy of granulocyte colony-stimulating factor in children with high-risk acute lymphoblastic leukemia. Blood 1996;87:3143-50
28. Sasse EC, Sasse AD, Brandalise SR, et al. Colony-stimulating factors for prevention of myelosuppressive therapy-induced febrile neutropenia in children with acute lymphoblastic leukemia. Cochrane Database Syst Rev 2005;(3):CD004139
29. Ehlers S, Herbst C, Zimmermann M, et al. Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse. J Clin Oncol 2010;28:2591-7
30. Pabst T, Vellenga E, van Putten W, Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON); German AML Study Group (AMLSG); Swiss Collaborative Group for Clinical Cancer Research (SAKK). Favorable effect of priming with granulocyte colonystimulating factor in remission induction of acute myeloid leukemia restricted to dose escalation of cytarabine. Blood 2012;119:5367-73
31. Taylor KM, Jagganath S, Spitzer G, et al. Recombinant human granulocyte colonystimulating factor hastens granulocyte recovery after high-dose chemotherapy and autologous bone marrow transplantation in Hodgkin?s disease. J Clin Oncol 1989;7:1791-9
32. Sheridan WP, Morstyn G, Wolf M, et al. Granulocyte colony stimulating factor and neutrophil recovery after high-dose chemotherapy and autologous bone marrow transplantation. Lancet 1989;2:891-5
33. Dührsen U, Villeval JL, Boyd J, et al. Effects of recombinant human granulocyte colony-stimulating factor on hematopoietic progenitor cells in cancer patients. Blood 1988;72:2074-81
34. Sheridan WP, Begley CG, Juttner CA, et al. Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapy. Lancet 1992;339:640-4
35. De Luca E, Sheridan WP, Watson D, et al. Prior chemotherapy does not prevent effective mobilisation by G-CSF of peripheral blood progenitor cells. Br J Cancer 1992;66:893-9
36. Bensinger W, Singer J, Appelbaum F, et al. Autologous transplantation with peripheral blood progenitor mononuclear cells collected after administration of recombinant granulocyte stimulating factor. Blood 1993;81:3158-63
37. Kim HK, De La Luz Sierra M, Williams CK, et al.F down-regulation of CXCR4 expression identified as a mechanism for mobilization of myeloid cells. Blood 2006;108:812-20
38. Ringdén O, Labopin M, Gorin NC, et al. Treatment with granulocyte colony-stimulating factor after allogeneic bone marrow transplantation for acute leukemia increases the risk of graft-versus-host disease and death: a study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2004;22:416-23
39. Khoury HJ, Loberiza FR Jr, Ringden O, et al. Impact of posttransplantation G-CSF on outcomes of allogeneic hematopoietic stem cell transplantation. Blood 2006;107:1712-16
40. Martin PJ. Choosing between GVHD and delayed engraftment. Nat Med 2009;15:363-4
41. Ho VT, Mirza NQ, del Junco D, et al. The effect of hematopoietic growth factors on the risk of graft-vs-host disease after allogeneic hematopoietic stem cell transplantation a meta-analysis. Bone Marrow Transplant 2003;32:771-5
42. Bonilla MA, Gillio AP, Ruggeiro M, et al. Effects of recombinant human granulocyte colony-stimulating factor on neutropenia in patients with congenital agranulocytosis. N Engl J Med 1989;320:1574-80
43. Welte K, Zeidler C, Reiter A, et al. Differential effects of granulocytemacrophage colony stimulating factor and granulocyte colony-stimulating factor in children with severe congenital neutropenia. Blood 1990;75:1056-63
44. Dale DC, Bonilla MA, Davis MS, et al. A randomized controlled phase III trial of recombinant human granulocyte colony-stimulating factor (filgrastim) for treatment of severechronic neutropenia. Blood 1993;81:2496-502
45. Bonilla MA, Dale D, Zeidler C, et al. Long-term safety of treatment with recombinanthuman granulocyte colony stimulating factor (r-metHuG-CSF) in patients with severe congenital neutropenias. Br J Haematol 1994;88:723-30
46. Welte K, Zeidler C, Dale DC. Severe congenital neutropenia. Semin Hematol 2006;43:189-95
47. Zeidler C, Germeshausen M, Klein C, Welte K. Clinical implications of ELA2-, HAX1-, and G-CSF-receptor (CSF3R) mutations in severe congenital neutropenia. Br J Haematol 2009;144:459-67
48. Rosenberg PS, Zeidler C, Bolyard AA, et al. Stable long-term risk of leukaemia in patients with severe congenital neutropenia maintained on G-CSF therapy. Br J Haematol 2010;150:196-9
49. Skokowa J, Steinemann D, Katsman-Kuipers J, et al. Cooperativity of RUNX1 and CSF3R Mutations in the Development of Leukemia in severe congenital Neutropenia: a Unique Pathway in Myeloid Leukemogenesis. Blood 2014. [Epub ahead of print]
50. Gascon P. Presently available biosimilars in hematology-oncology: G-CSF. Target Oncol 2012
51. Gravel P, Naik A, Le Cotonnec J-Y. Biosimilar rhG-CSFs: how similar are they? Target Oncol 2012;7(Suppl 1):3-16.
52. Waller CF, Bronchud M, Mair S, Challand R. Pharmacokinetic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010;89:927-33
53. Waller CF, Bronchud M, Mair S, Challand R. Comparison of the pharmacodynamic profiles of a biosimilar filgrastim and Amgen filgrastim: results from a randomized, phase I trial. Ann Hematol 2010;89:971-8
54. Waller CF, Semiglazov VF, Tjulandin S, et al. A phase III randomized equivalence study of biosimilar filgrastim versus Amgen filgrastim in patients receiving myelosuppressive chemotherapy for breast cancer. Onkologie 2010;33:504-11
55. Gatzemeier U, Ciuleanu T, Dediu M, et al. XM02, the first biosimilar G-CSF, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with small cell or non-small cell lung cancer receiving platinum-based chemotherapy. J Thorac Oncol 2009;4:736-40
56. Engert A, Griskevicius L, Zyuzgin Y, et al. XM02, the first granulocyte colony-stimulating factor biosimilar, is safe and effective in reducing the duration of severe neutropenia and incidence of febrile neutropenia in patients with non-Hodgkin lymphoma receiving chemotherapy. Leuk Lymphoma 2009;50:374-9
57. Lefrere F, Brignier AC, Elie C, et al. First experience of autologous peripheral blood stem cell mobilization with biosimilar granulocyte colony-stimulating factor. Adv Ther 2011;28:304-10
58. Ianotto JC, Tempescul A, Yan X, et al. Experience (1 year) of G-CSF biosimilars in PBSCT for lymphoma and myeloma patients. Bone Marrow Transplant 2012;47:874-6
59. Shaw BE, Confer DL, Hwang WY, et al. Concerns about the use of biosimilar granulocyte colony-stimulating factors for the mobilization of stem cells in normal donors: position of the World Marrow Donor Association. Haematologica 2011;96:942-7
60. Gascón P, Tesch H, Verpoort K, et al. Clinical experience with Zarzio in Europe: what have we learned? Support Care Cancer 2013;21:2925-32
61. Aapro M, Cornes P, Abraham I. Comparative cost-efficiency across the European G5 countries of various regimens of filgrastim, biosimilar filgrastim, and pegfilgrastim to reduce the incidence of chemotherapy-induced febrile neutropenia. J Oncol Pharm 2012;18:171-9